2015


To access this material please log in or register

Register Authorize
2015/№6

Current diuretic therapy: advantages of torasemide in the treatment of heart failure

Khazova E. V., Bulashova O. V., Gazizyanova V. M., Nasybullina A. A., Malkova M. I.
State Budgetary Educational Institution “Kazan State Medical University” of the RF Ministry of Health Care, Butlerova 49, Kazan 420012

Keywords: diuretics, quality of life, treatment, torasemide, CHF

DOI: 10.18087/rhfj.2015.6.2107

Diuretic therapy remains one of the major approaches in the treatment of HF. Therefore, the question, which diuretic is currently the most effective and safe, is logical. This review focuses on results of studies comparing efficacy and safety of torasemide and other diuretics. It has been shown that torasemide has additional benefits with respect of reducing mortality and is clinically more effective than furosemide and other diuretics. The torasemide treatment improves quality of life due to beneficial effects of clinical picture and social adaptation of patients.
  1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan;8 (1):30–41.
  2. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003 Mar;24 (5):442–63.
  3. Гуревич М. А. Хроническая сердечная недостаточность. Руководство для врачей. 5‑е изд. – М.: Практическая медицина, 2008. – 414с.
  4. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29 (19):2388–442.
  5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33 (14):1787–847.
  6. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther. 1987 Aug;42 (2):187–92.
  7. Ghys A, Denef J, Delarge J, Georges A. Renal effects of the high ceiling diuretic torasemide in rats and dogs. Arzneimittelforschung. 1985;35 (10):1527–31.
  8. Сидоренко Б. А., Преображенский Д. В., Батыралиев Т. А., Першуков И. В., Махмутходжаев С. А. Место диуретиков в лечении хронической сердечной недостаточности. Часть I. Кардиология. 2005;45 (8):76–83.
  9. Bоlke T, Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs of today. 1994;30 (8):1–28.
  10. Метелица В. И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3‑е издание. – М.: Медицинское информационное агентство, 2005. – 1540с.
  11. Broekhuysen J, Deger F, Douchamps J, Ducarne H, Herchuelz A. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31 (Suppl): 29–34.
  12. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991 Nov 26;205 (2):145–50.
  13. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63 (3):PL45–50.
  14. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004 Jun 2;43 (11):2028–35.
  15. Achhammer I, Hacker W, Glocke M. Efficacy and safety of torasemide in patients with chronic heart failure. Arzneimittelforschung. 1988 Jan;38 (1A): 184–7.
  16. Goebel KM. Six-week study of torsemide in patients with congestive heart failure. Clin Ther. 1993 Nov-Dec;15 (6):1051–9.
  17. Fassbinder W, Achhammer I, Ziegler J. Improved prognosis of patients with chronic heart failure by an optimized diuretic therapy with the new loop diuretic torasemide. J Am Coll Cardiol. 1998;31 (Suppl C): 1401.
  18. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 1999 May;21 (5):854–66.
  19. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002 Aug;4 (4):507–13.
  20. Жиров И. В., Горюнова Т. В., Осмоловская Ю. Ф., Терещенко С. Н. Место торасемида замедленного высвобождения в лечении ХСН. Русский медицинский журнал. 2014;22 (6):436–9.
  21. Беркинбаев C. Ф., Джунусбекова Г. А., Исанбекова А. Х. Клини­ческая эффективность петлевого диуретика торасемида в лечении хронической сердечной недостаточностью Результаты казахстанского многоцентрового исследования «ПОЭТ». Рациональная фармакология в кардиологии. 2014;10 (5):495–9.
  22. Беловол А. Н., Князькова И. И., Цыганков А. И., Толкачева И. А., Гребенюк О. В., Плиева И. Ю. Оптимизация лечения больных хронической сердечной недостаточностью в сочетании с хроническим обструктивным заболеванием легких. Рациональная фармакотерапия. 2014;4 (33):52–7.
  23. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001 Nov;111 (7):513–20.
  24. Spannheimer A, Muller К, Falkenstem P, Reitberger U, Gutzwiller F, Follath F. Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide? Praxis (Bern 1994). 2002 Sep 11;91 (37):1467–75.
  25. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. Диуретическая терапия Эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН). Журнал Сердечная Недостаточность. 2011;12 (1):3–10.
  26. Wittig T, Medert G. Torasemide in patients with chronic heart failure. Results of clinical administration in general practice. Fortschr Med. 1996 Jan 30;114 (3):24–8.
  27. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail. 2003 Dec;5 (6):793–801.
  28. Lopez B, Querejeta R, Gonzalez A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009 Feb;53 (2):236–42.
  29. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007 Feb 20;115 (7):888–95.
  30. Lоpez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007 Aug 28;50 (9):859–67.
  31. Агеев Ф. Т., Жубрина Е. С., Гиляревский С. Р., Мареев В. Ю., Хосева Е. Н., Голшмид М. В. и др. Сравнительная эффективность и безопасность длительного применения торасемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Журнал Сердечная Недостаточность. 2013;14 (2):55–62.
  32. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y et al. Effects of torasemide on cardiac sympathetic nerve activi­ty and left ventricular remodeling in patients with congestive heart failure. Heart. 2006 Oct;92 (10):1434–40.
  33. TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011 Sep;33 (9):1204–13.
  34. Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009 Jun;53 (6):468–73.
  35. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res. 2005 Oct 1;68 (1):118–27.
  36. Yamato M, Sasaki Т, Honda K, Fukuda M, Akutagawa O, Okamoto M, Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003 May;67 (5):384–90.
  37. Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract. 1998 Oct;52 (7):467–71.
  38. Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000 May;17 (5):429–40.
Khazova E.V., Bulashova O. V., Gazizyanova V. M., Nasybullina A. A., Malkova M.I. Current diuretic therapy: advantages of torasemide in the treatment of heart failure. Russian Heart Failure Journal. 2015;16 (6):384–390

To access this material please log in or register

Register Authorize
Ru En